

RESPONSE TO SGX REGCO'S QUERY DATED 15 AUGUST 2025

The Board of Directors (the "**Board**") of Cordlife Group Limited (the "**Company**") and together with its subsidiaries, the "**Group**", wishes to announce the information set out below in response to a query received from Singapore Exchange Regulation Pte Ltd. ("**RegCo**") on 15 August 2025 in relation to the Company's announcement, dated 14 August 2024 on the appointment of Ms. Wu Yifei ("**Ms. Wu**") as the Group Chief Financial Officer of the Company.

RegCo's Query

"Please provide details of the nominating committee's basis for assessing Ms. Wu's suitability for this role, in particular, her familiarity with the rules, regulations and practices of countries in which the Company operates in, and whether she has experience with preparing accounts in accordance with the Singapore Financial Reporting Standards".

Company's Response

Ms. Wu has over 20 years of professional experience in auditing and financial management, having served as a C-suite executive at several publicly listed healthcare companies and previously practicing as an auditor. Her experience has equipped her with practical expertise and familiarity with compliance, transparency, and accountability standards expected of listed issuers.

Before joining the Company as Group Finance Director in June 2025, Ms. Wu was the Group Chief Financial Officer and Board Secretary of PharmaBlock Sciences (Nanjing), Inc. ("**PharmaBlock**"), a company listed on the Shenzhen Stock Exchange. In her roles, she oversaw PharmaBlock's overall financial strategy, investors' outreach and ensuring PharmaBlock's compliance with corporate governance and regulatory requirements.

Ms. Wu also served as the Group Chief Financial Officer of Efort Intelligent Equipment Co., Ltd. ("**Efort Intelligence**") from April 2019 to May 2021, a company listed on the Shanghai Stock Exchange. There, she established and standardised Efort Intelligence's financial reporting structure and oversaw its initial public offering on the Shanghai Stock Exchange STAR Market. At the time of listing, Efort Intelligence had more than 20 subsidiaries, and over 60% of them were located in Brazil, India, Italy and Poland.

Ms. Wu also previously served as the Finance Director of Simcere Pharmaceutical Group, during the period in which the company was listed on the New York Stock Exchange. In this role, she oversaw the company's financial filings with the Securities and Exchange Commission and managed the company's audit processes in compliance with the Sarbanes-Oxley Act of the United States of America.

Ms. Wu has over 10 years of audit experience, having previously served as an auditor at Deloitte Touche Tohmatsu Certified Public Accountants LLP and Jiangsu Talent CPA Firm. During her time at these firms, she led a variety of initial public offering and recurring compliance audits for clients listed in the People's Republic of China, Hong Kong and the United States of America.

Ms. Wu possesses substantial knowledge and experience in preparing financial statements in accordance with the International Financial Reporting Standards ("**IFRS**") issued by the International Accounting Standards Board. These standards and interpretations are equivalent to the Singapore Financial Reporting Standards (International), being the applicable accounting standards adopted by the Group.

Ms. Wu holds a Bachelor of Science in International Accounting, with a minor in English, from Nanjing University. She is a Certified Public Accountant in both the United States of America ("**AICPA**") and the People's Republic of China ("**CICPA**") and is also a Chartered Global Management Accountant ("**CGMA**") and Certified Tax Agent ("**CTA**").

Accordingly, the Nominating Committee ("**NC**") assessed Ms Wu to be suitable to be appointed as Group Chief Financial Officer of the Company, considering:

- (a) her qualifications and past working experience as listed above which, in particular, cover management, finance and audit experience with listed healthcare companies;
- (b) performance in her role as the Company's Group Finance Director; and
- (c) her finance and audit experience in IFRS reporting which would be directly relevant to the Company's financial reporting obligations in Singapore.

For and on behalf of the Board
CORDLIFE GROUP LIMITED

Cheok Hui Yee
Goh Xun Er
Company Secretaries

19 August 2025